CKDCE3

Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty	Relationship Identified With:
Jonathan Barratt, PhD, FRCP	Research Grants: argenx; Calliditas Therapeutics; Chinook Therapeutics; Galapagos NV; GSK, Novartis; Travere Therapeutics Medical/Scientific Advisor: Alnylam Pharmaceuticals; argenx; Astellas Pharma; BioCryst Pharmaceuticals; Calliditas Therapeutics; Chinook Therapeutics; Dimerix; Galapagos NV; Novartis; Omeros; Travere Therapeutics; UCB; Vera Therapeutics; Visterra

Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Charles V. Pollack Jr., MD; Kim Cheramie, MSN, RN-BC; Patrick Hayes and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.

Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA
Category 1 Credits^TM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact
Hours.
AcademicCME designates this continuing education activity for 0.50 CPE Contact
Hours (0.05 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-24-
019-H01-P).
Learners should only claim credit commensurate with the extent of their participation.

This activity has been supported by an independent educational grant from Travere Therapeutics.

Name*

First NameLast Name

Email*

example@example.com

I am a:

If Physician, I am primarily a:

If Pharmacist, DOB:*

Date

If Pharmacist, NABP ID#:*

I work primarily in:

I work primarily in the:

Inpatient settingOutpatient settingOther

I engaged with this program via:

I would recommend this program and format to my colleagues.

YesNo

I am aware of CE/CME courses available on Twitter from @ckd_ce.

TrueFalse

1. Which of the following is considered the primary goal in managing IgA nephropathy (IgAN)?*

a. Complete elimination of proteinuriab. Delay of end-stage renal disease (ESRD) progressionc. Reduction in serum IgA levelsd. Reduction in T-cell response

2. Which of the following biomarkers is often monitored to assess disease activity and progression in IgAN?*

a. C-reactive protein (CRP)b. Serum IgA levelsc. Urinary protein-to-creatinine ratiod. Hemoglobin levels

Attestation to Time Spent on Activity:
AcademicCME designates this activity for a maximum of 0.50 AMA PRA Category 1 Credits^TM, 0.50 CNE Contact Hours, or 0.50 CPE Contact Hours (0.05 CEUs) UAN # JA4008190-0000-24-019-H01-P for participation in the full educational activity.

I participated in this activity and claim:*

AMA PRA Category 1 Credits^TMCNE Contact HoursCPE Contact Hours (CEUs)

Date

credits